These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 3151334)

  • 1. Antibacterial activity of ciprofloxacin against immobilized Pseudomonas aeruginosa.
    Konrad-Dalhoff I; Dalhoff A
    Chemioterapia; 1987 Jun; 6(2 Suppl):137-8. PubMed ID: 3151334
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro activity of meropenem in combination with ciprofloxacin against clinical isolates of Pseudomonas aeruginosa.
    Solak S; Willke A; Ergönül O; Tekeli E
    Int J Antimicrob Agents; 2005 Feb; 25(2):181-2. PubMed ID: 15664492
    [No Abstract]   [Full Text] [Related]  

  • 3. Emergence of ciprofloxacin-resistant pseudomonas in chronic suppurative otitis media.
    Jang CH; Park SY
    Clin Otolaryngol Allied Sci; 2004 Aug; 29(4):321-3. PubMed ID: 15270816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of temperature on the bactericidal activities of ciprofloxacin and levofloxacin against Escherichia coli and Pseudomonas aeruginosa.
    Parte AC; Smith JT
    Microbios; 1994; 80(322):31-9. PubMed ID: 7854197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An in vitro investigation of levofloxacin and ciprofloxacin against clinical isolates of Pseudomonas aeruginosa.
    Segatore B; Perilli M; Larosa M; Setacci D; Celenza G; Amicosante G
    Int J Antimicrob Agents; 2007 Oct; 30(4):374-6. PubMed ID: 17659863
    [No Abstract]   [Full Text] [Related]  

  • 6. Activity of 4-quinolones against Pseudomonas aeruginosa.
    Morissey I; Smith JT
    Arzneimittelforschung; 1994 Oct; 44(10):1157-61. PubMed ID: 7818593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity testing of Pseudomonas aeruginosa to ciprofloxacin: comparison of the modified Stokes' method with MIC results obtained by the Etest.
    Galloway A; Wright J; Murphy O; Dickinson G
    J Antimicrob Chemother; 1999 Feb; 43(2):314-5. PubMed ID: 11252344
    [No Abstract]   [Full Text] [Related]  

  • 8. [Synthesis and antibacterial activity of N-(aroylalkyl) ciprofloxacin].
    Hu AX; Wang YT; You TB
    Yao Xue Xue Bao; 2007 Aug; 42(8):854-7. PubMed ID: 17944234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of antibiotic sequence on combination regimens against Pseudomonas aeruginosa in a multiple-dose, in vitro infection model.
    Zelenitsky SA; Iacovides H; Harding GK; Ariano RE
    Diagn Microbiol Infect Dis; 2004 May; 49(1):67-70. PubMed ID: 15135504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial effect of octylcyanoacrylate against ciprofloxacin-resistant Pseudomonas aeruginosa isolates from patients with chronic suppurative otitis media.
    Jang CH; Park H; Cho YB; Choi CH; Song C
    In Vivo; 2009; 23(1):183-5. PubMed ID: 19368147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial activity of fosfomycin against multidrug-resistant Pseudomonas aeruginosa in vitro.
    Kobayashi Y; Sumitani Y; Sugita K; Aikawa N
    Int J Antimicrob Agents; 2007 Dec; 30(6):563-4. PubMed ID: 17900870
    [No Abstract]   [Full Text] [Related]  

  • 12. Selection of cross-resistance following exposure of Pseudomonas aeruginosa clinical isolates to ciprofloxacin or cefepime.
    Alyaseen SA; Piper KE; Rouse MS; Steckelberg JM; Patel R
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2543-5. PubMed ID: 15917569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa.
    Chin JN; Jones RN; Sader HS; Savage PB; Rybak MJ
    J Antimicrob Chemother; 2008 Feb; 61(2):365-70. PubMed ID: 18079128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro bactericidal activity of allicin combined with cefoperazone, tobramycin and ciprofloxacin.
    Cai Y; Wang R; An MM; Liang BB; Fang Y
    Int J Antimicrob Agents; 2008 Feb; 31(2):179-80. PubMed ID: 18083012
    [No Abstract]   [Full Text] [Related]  

  • 15. Ciprofloxacin-resistant Pseudomonas keratitis.
    Garg P; Sharma S; Rao GN
    Ophthalmology; 1999 Jul; 106(7):1319-23. PubMed ID: 10406614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa.
    Hansen GT; Zhao X; Drlica K; Blondeau JM
    Int J Antimicrob Agents; 2006 Feb; 27(2):120-4. PubMed ID: 16426820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ciprofloxacin in vitro activity alone and in combination against clinical isolates of glucose nonfermenting bacteria.
    Marklein G; Lotze G; Ungerechts J
    J Chemother; 1989 Jul; 1(4 Suppl):156-9. PubMed ID: 16312350
    [No Abstract]   [Full Text] [Related]  

  • 18. Ciprofloxacin monotherapy and bacterial keratitis.
    Katz HR
    Ophthalmology; 1999 Oct; 106(10):1853-4. PubMed ID: 10519570
    [No Abstract]   [Full Text] [Related]  

  • 19. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
    Pasquali F; Manfreda G
    Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Optimization of antibiotics in combination].
    Zhang LH; Wang LF; Meng ZY; Yu QP; Gao BQ; Ba T; Wang XD; Ma WH; Li YY; Zhang J
    Zhonghua Shao Shang Za Zhi; 2008 Apr; 24(2):93-6. PubMed ID: 18785405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.